Natera SEC and chief legal officer sells $485,106 in shares By Investing.com

Daniel Rabinowitz, Secretary and Chief Legal Officer at Natera, Inc. (), recently sold shares of the company’s common stock totaling $485,106, according to a recent regulatory filing.

On July 27, 2026, Mr. Rabinowitz disposed of 884 shares at a price of $260.4908 per share. The following day, July 28, 2026, he sold an additional 1,003 shares. These shares were sold at a weighted average price of $254.0704, with individual transaction prices ranging from $254.0696 to $254.3500 per share. Overall, the sales prices for these transactions ranged between $254.0704 and $260.4908.The transactions come as Natera shares trade near $254, up significantly from their 52-week low of $131.81, reflecting an impressive 80% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate. Investors can access the comprehensive Pro Research Report for deeper insights into Natera’s valuation and 10+ additional ProTips.

The sales were primarily conducted to satisfy tax withholding and remittance obligations related to the vesting of Restricted Stock Units (RSUs). These transactions were made pursuant to Rule 10b5-1(c) trading plans, which were established in connection with RSU grants from January 26, 2024, and January 27, 2023.

Following these reported transactions, Mr. Rabinowitz directly holds 170,407 shares of Natera common stock.

In other recent news, Natera Inc. announced that its Signatera test has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation, which includes the assay, specimen collection kit, and associated software. Additionally, Natera published data in JAMA Oncology evaluating the Signatera test in patients with resected colorectal liver metastases, demonstrating its potential in predicting chemotherapy benefits. The company has also partnered with Aveta Biomics for a global Phase 3 clinical trial to evaluate APG-157 in head and neck cancer patients, utilizing the Signatera test to assess treatment response.

Furthermore, Bernstein SocGen Group resumed coverage on Natera with an outperform rating, highlighting the company’s growth potential in minimal residual disease testing, particularly in Japan. The anticipated commercial launch and PMDA reimbursement in Japan are expected to drive volumes. Meanwhile, TD Cowen reported an increase in short interest for several life science stocks, including Natera, as of July 15.

These developments reflect Natera’s ongoing efforts to expand its testing capabilities and market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.